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S U M M A R Y
Objective: Brucellosis is a zoonosis with high morbidity in humans. This disease has gained interest
recently due to its re-emergence and potential for weaponization. Pregnant women with this disease can
develop severe complications. Its association with adverse obstetric outcomes is not clearly understood.
The objective of this study was to describe the obstetric outcomes of brucellosis in pregnancy.
Methods: Cases of pregnant women with active brucellosis seen at the Hospital Nacional Cayetano
Heredia from 1970 to 2012 were reviewed. Diagnostic criteria were a positive agglutination test and/or
positive blood/bone marrow culture. Presentation and outcomes data were collected. The Chi-square
test was used for nominal variables. A p-value of <0.05 indicated signiﬁcance.
Results: One hundred and one cases were included; 27.7% had a threatened abortion/preterm labor,
12.8% experienced spontaneous abortion, 13.9% preterm delivery, 8.1% fetal death, and 1.1% congenital
malformations. There was one maternal death secondary to severe sepsis. After delivery, neonatal death
occurred in 8.1%, low birth weight in 14.5%, and congenital brucellosis in 6.4%. The most common
treatment was aminoglycosides plus rifampicin (42.2% of cases). Complication rates decreased if
treatment was started within 2 weeks of presentation (p < 0.001).
Conclusions: This is the largest series of brucellosis in pregnancy reported in the literature. Brucella
presents adverse obstetric outcomes including fetal and maternal/neonatal death. Cases with
unexplained spontaneous abortion should be investigated for brucellosis. Prompt treatment is
paramount to decrease the devastating outcomes.
 2015 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Brucellosis is a zoonosis with high morbidity in animals and
humans.1,2 It is a chronic granulomatous infection,3 capable of
affecting any organ system,3 and may masquerade as a myriad of
entities.4 It is the most widespread zoonosis worldwide, with
500 000 new cases reported annually, and is an important cause of
economic loss in many countries.3,5 Of the known species, Brucella
melitensis causes the majority of cases globally and has a
predisposition for recurrence and chronic stages.1
In endemic countries, brucellosis is typically acquired through
the consumption of dairy products. It affects both genders equally,1
and special attention must be given to those with an impaired
immunological status such as pregnant women, since entities such* Corresponding author. Tel.: +1 816 404 5155; fax: +1 816 404 5152.
E-mail address: vilchezlagosg@umkc.edu (G. Vilchez).
http://dx.doi.org/10.1016/j.ijid.2015.06.027
1201-9712/ 2015 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/4.0/).as typhoid fever, inﬂuenza, and hepatitis E have been shown to be
more severe in pregnant women,6 presenting higher mortality rates.
Brucellosis in pregnancy is associated with adverse outcomes
such as spontaneous abortion, preterm delivery, chorioamnionitis,
and fetal death.7 However, it is not clear whether these outcomes
are more common than in other infectious diseases.8 The incidence
of abortion is higher and prompt therapy can be life-saving for the
fetus.9
A renewed scientiﬁc interest in brucellosis has been fuelled by
its recent re-emergence and enhanced surveillance,5 its potential
to be weaponized,10 and growing international tourism and
migration. However, reports on brucellosis in pregnancy published
in the literature are scarce,9,11–13 thus studies focusing on clinical
presentation, adverse obstetric outcomes, and treatment prognosis
are warranted. In this scenario, the objective of the present study
was to analyze the obstetric outcomes of pregnancies complicated
by brucellosis. A 40-year treatment experience of brucellosis (by B.
melitensis) in pregnancy in an endemic area is presented.ious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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The Institutional Review Boards Committee of the Cayetano
Heredia Peruvian University and the Cayetano Heredia National
Hospital (HNCH) reviewed and approved the methodology of
this study. The design of the study was a retrospective case
series.
Cases with a diagnosis of brucellosis in pregnancy, including
those with known brucellosis who became pregnant during the
course of the disease, were selected. These cases were identiﬁed
from patients seen at the HNCH, in the departments of infectious
diseases and tropical medicine, and obstetrics and gynecology, and
at the infectious diseases in pregnancy clinic, a private clinic of one
of the authors (E.G.). Cases initially presenting to the study
institution, and also those referred from other institutions
(hospitals, private clinics, primary care centers) for consultation
and more sub-specialized management, were included. All cases
had been identiﬁed and followed prospectively for other research
purposes as part of an ongoing research protocol since 1970 – the
Brucellosis Study Protocol – which identiﬁes and follows patients
with brucellosis seen at the study institution.
To ensure that all cases were included, all HNCH discharge
and consultation registries for the period 1970 to 2012 were
reviewed, and newly identiﬁed cases were contacted by phone or
home visit.
Study inclusion criteria were the following: patients with a
current pregnancy or recent delivery/abortion; patients with
known brucellosis who became pregnant or had a spontaneous
abortion during the course of the disease; and diagnosis of
brucellosis, made according to standard criteria: (1) agglutina-
tion test positive for B. melitensis (in plate 1:160; in tube
agglutination standard (SE) 1:160, blocking antibody titer (BAB)
1:80); (2) positive culture for B. melitensis in blood or bone
marrow. Cases with inadequate follow-up or incomplete data
were excluded.
Data collection forms designed prospectively for the Brucellosis
Study Protocol were reviewed: the Brucellosis Study Protocol form
includes information related to demographics, risk factors, clinical
presentation (signs/symptoms, duration of the disease, clinical
stage, severity), and laboratory data; the Brucellosis in Pregnancy
Study form includes information regarding pregnancy outcomes
and treatment; the Follow-up Visit forms collect information from
follow-up visits related to the resolution of symptoms, recurrence,
and other treatment regimens.
The clinical stage of the disease was deﬁned according to the
duration of symptoms as acute (<8 weeks), subacute (8 weeks to
1 year), or chronic (>1 year). Recurrence was deﬁned as a return of
symptoms or new symptoms after complete treatment. Risk
factors for brucellosis included a history of brucellosis, history of
contact, consumption of unpasteurized dairy products, and certain
occupations (healthcare provider, veterinarian, farmer, and
butcher). Adverse obstetric history was deﬁned as a history of
spontaneous abortion and/or preterm delivery.
Hematological disease severity was classiﬁed as mild (episodes
of bleeding such as epistaxis or microhematuria with a normal
platelet count), moderate (purpuric syndrome), or severe (severe
bleeding disorders such us gastrointestinal bleeding, hemoptysis
with no other pulmonary disease, severe thrombocytopenia <50 
109 platelets/l, and disseminated intravascular coagulation). Liver
disease severity was classiﬁed as mild (elevation of liver enzymes
and/or bilirubin with hepatomegaly, no jaundice), moderate
(jaundice with elevation of liver enzymes and/or bilirubin between
2- and 10-fold), or severe (jaundice with elevation of liver enzymes
and/or bilirubin over 10-fold). Joint disease was deﬁned as
peripheral (clinical diagnosis with or without radiological conﬁr-
mation) or sacroiliitis (pain in the sacroiliac joint that could bereproduced by speciﬁc joint examination maneuvers independent
of radiological ﬁndings), as described previously.14
The severity of the disease was deﬁned as mild (no complications
or depression only), moderate (complications such as arthritis, mild/
moderate liver disease, peripheral neurological involvement, psy-
chiatric disorder, and dermatological conditions in stable condition),
or severe (disseminated intravascular coagulation, severe central
nervous system disease, respiratory distress syndrome, liver failure,
endocarditis, and cardiac tamponade).
During pregnancy, treatment regimens included rifampicin,
macrolides, aminoglycosides, and co-trimoxazole. Tetracyclines
were not used. A combination of two drugs was prescribed for 4–6
weeks, with aminoglycosides for 7–10 days. After delivery/abortion,
treatment regimens consisted of tetracyclines plus aminoglycosides
or rifampicin. Tetracyclines were avoided during lactation, and when
tetracyclines were ordered, lactation was discouraged. Macrolides
were used in speciﬁc cases.
Patients were followed systematically at the HNCH infectious
diseases clinic by one of the authors (E.G.), at the department of
obstetrics and gynecology by obstetricians, and at the department
of neonatology that was consulted during prenatal care. At delivery
there was a special evaluation of the newborn by neonatologists.
Upon mother and newborn discharge from the hospital, mothers
were counseled regarding newborn follow-up. When a patient did
not return for follow-up or delivered at another facility, attempts
were made to contact the patient by phone or home visit, and
information was collected.
All data were analyzed using SPSS software version 20. All
frequencies were represented in percentages. The Chi-square test
was used to compare nominal variables. A p-value of <0.05 with a
95% conﬁdence interval was used to indicate statistical signiﬁ-
cance.
3. Results
A total of 133 cases were identiﬁed; 32 cases were excluded
(27 due to insufﬁcient data and ﬁve withdrew from the study).
Thus, 101 cases were included for analysis (Figure 1).
3.1. Demographics
Maternal age at presentation ranged from 15 to 45 years (mean
26.1 years), with most aged between 25 and 29 years (Table 1). In
100 cases (99.1%), risk factors for brucellosis were identiﬁed; 90.8%
reported the ingestion of non-pasteurized dairy products. An
adverse obstetric history was associated with a chronic course of
the disease (p = 0.01, Table 1). The trimester at presentation was
available for 99 cases, and was most commonly the ﬁrst trimester
(Table 1).
3.2. Clinical presentation
All cases presented with clinical signs/symptoms, the most
common being fever (Table 2). Most were in the acute stage
(p = 0.01), with mild severity (Table 2).
3.3. Laboratory results and diagnostic criteria
At presentation, brucellosis was top in the differential at the
ﬁrst visit in 50 cases (49.5%), was suspected in 21 cases (20.8%), and
was not part of the differential in 30 cases (29.7%). Blood cell count
data were available for 91 cases. Anemia was found in 63 cases
(69.2%), leukocytosis in 10 (11%), leukopenia in 12 (13.2%), and
lymphopenia in 29 (31.9%). Thrombocytopenia developed in four
out of 26 cases (15.4%). All cases had positive agglutination titers,
and blood culture was positive in 33 cases (32.7%).
Table 2
Clinical presentation of brucellosis in pregnancy.
Number of cases Frequency
Symptoms
Fever 98 97.0%
Malaise 86 85.1%
Diaphoresis 78 77.2%
Headache 77 76.2%
Hyporexia 63 62.4%
Arthralgia 57 56.4%
Myalgia 51 50.5%
Figure 1. Distribution of cases of brucellosis in pregnancy by year of the study (N = 101).
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Fifty-seven cases (56.4%) presented with medical complica-
tions, the most common being a hematological disease (26.4%).
Liver disease and joint disease were associated with acute and
subacute stages, respectively (p < 0.001).
3.5. Treatment
Of the 101 patients, 99 received treatment at the study
institution and two cases received treatment at another facility.
These two cases were discharged in a stable condition without a
speciﬁc diagnosis. Subsequent results detected brucellosis.
Attempts to contact patients were unsuccessful. Of 99 treated
cases, 64.6% were treated during pregnancy and 35.4% after
delivery/spontaneous abortion (Table 3). During pregnancy, the
most common treatment regimen was aminoglycoside plus
rifampicin (42.2%) (Table 3). Postpartum, the most common
regimen was tetracycline plus rifampicin (Table 3).
3.6. Obstetric complications before delivery
Almost 28% of cases presented obstetric complications.
Threatened abortion (12.9%) presented more frequently in cases
in the acute stage, with the mild form, in the ﬁrst trimester, andTable 1
Demographics at presentation of brucellosis in pregnancy (N = 101)
Number of cases Frequency
Maternal age range (years)
15–19 3 3.0%
20–24 31 30.7%
25–29 35 34.7%
30–34 21 20.8%
>35 11 10.9%
Parity
Primiparous 28 31.8%
Multiparous 60 68.2%
Unknown 13
Obstetric history
Normal 31 51.7%
Abnormal 29 48.3%
History of spontaneous abortion 28 46.7%
History of preterm delivery 14 23.3%
Trimester of presentation
First 45 45.5%
Second 22 22.2%
Third 32 32.3%
Unknown 213with inadequate treatment. Preterm labor (16.8%) was more
common in cases in the acute stage, with the mild form, in the third
trimester, and without adequate treatment (Table 4).
3.7. Obstetric outcomes
Of 86 cases, 58.1% delivered at term and 41.8% had adverse
outcomes (Table 5). Term deliveries were more common when the
disease presented in the acute stage, with the mild form, during the
third trimester, and without adequate treatment. Fifteen cases
were not followed-up or delivered at another institution.
Spontaneous abortion was more common in subacute stages
with the mild form, in the ﬁrst trimester, and without adequate
treatment. Spontaneous preterm delivery was more common inLower back pain 50 49.5%
Chills 49 48.5%
Nausea 39 38.6%
Constipation 31 30.7%
Vomiting 22 21.8%
Abdominal pain 22 21.8%
Cough 18 17.8%
Vaginal bleeding 16 15.8%
Epistaxis/petechiae 11 10.9%
Diarrhea 9 8.9%
Depression 7 6.9%
Dysuria/urinary frequency 6 5.9%
Odynophagia 4 4.0%
Dyspnea 2 2.0%
Signs
Fever 68 67.3%
Hepatomegaly 47 46.5%
Splenomegaly 35 34.7%
Jaundice 22 21.8%
Adenomegaly 21 20.8%
Arthritis 17 16.8%
Vaginal bleeding 12 11.9%
Epistaxis/petechiae 10 9.9%
Neurological symptoms 5 5.0%
Abnormal lung auscultation 3 3.0%
Erythema nodosum 2 2.0%
Table 3
Antibiotic regimens used in brucellosis in pregnancy (N = 101a)
During pregnancy (n = 64)
First trimester Second trimester Third trimester Total Frequency
Regimen Number of cases
Aminoglycoside + rifampicin 10 7 10 27 42.2%
Aminoglycoside + co-trimoxazole 2 0 0 2 3.1%
Aminoglycoside + tetracycline 1 0 0 1 1.6%
Aminoglycoside + erythromycin 3 4 3 10 15.6%
Rifampicin + co-trimoxazole 4 2 7 13 20.3%
Other regimens 3 4 4 11 17.2%
After delivery/abortion (n = 35)
Tetracycline + aminoglycoside N/A 14 40.0%
Tetracycline + rifampicin 16 45.7%
Erythromycin + aminoglycoside 1 2.9%
Aminoglycoside + rifampicin 1 2.9%
Other regimens 3 8.6%
N/A, not applicable.
a Two of the 101 cases did not receive treatment.
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adequate treatment (Table 5).
Fetal death was more common in the acute/subacute stage, with
the moderate form, in the ﬁrst trimester, and without adequate
treatment. There was only one case of congenital malformation that
presented in the acute stage, with the mild form, in the second
trimester, and with adequate treatment (Table 5).
The timing of treatment during pregnancy was related to
adverse obstetric outcomes in 64 cases. Adverse outcomes were
less frequent if treatment was started at 2 weeks of disease
presentation (p < 0.001).
3.8. Mortality
There was one case of maternal death, in a 31-week pregnant
woman who presented with a 3-week history of the disease. The
initial diagnosis was urinary tract infection with reactive hepatitis.
The patient died on the third day of hospitalization secondary to
disseminated intravascular coagulation. The diagnosis criteria for
brucellosis were serological (agglutinins standard (ST) 1:1280).
Blood culture was positive on the second day and she was treatedTable 4
Obstetric complications during brucellosis in pregnancy (N = 101a)
At least one complication (n = 28)
Threatened abortion
(n = 13)
Preterm labor
(n = 17)
Number of cases
Clinical stage
Acute 6 8
Subacute 4 4
Chronic 3 5
Trimester
First 7 2
Second 3 7
Third 3 8
Severity
Mild 8 11
Moderate 5 5
Severe 0 1
Treatment
Not treated 9 13
Treated 4 4
a Seventy-three of the 101 cases did not present any complications during
pregnancy.for 1 day before death. The autopsy showed pulmonary, renal, and
liver disease.
3.9. Neonatal outcomes
Of 86 cases with follow-up, 50 (58.1%) delivered at term and 12
(13.95%) preterm. Newborns had macrosomia in two cases (3.2%),
normal birth weight in 51 (82.2%), and low birth weight in nine
(14.5%). There were four cases (6.4%) with congenital brucellosis
and seven neonatal deaths (11.3%).
4. Discussion
Brucellosis in pregnancy is thought to be uncommon. The ﬁrst
report was made in 1906 by Devoir (a case of abortion in a pregnant
farmer).7 The ﬁrst series was published in 1938 by Vecchio
(59 cases) in which 78.6% had a spontaneous abortion.15 Elshamy
and Ahmed reported an incidence of 12.2% (2008),12 and Khan et al.
reported a cumulative incidence of 1.3 cases/1000 obstetric
discharges and 0.3 cases/1000 hospital admissions (2001).9 Sharif
et al. found 3.5% of positive Brucella titers among pregnant
Egyptian women (1990).11 In this study, a mean of 2.3 cases per
year was found (Figure 1).
In the present study cohort, the disease affected 25–29-year-
olds most commonly vs. other studies.8,9,12,13,16 A family history of
brucellosis and stockbreeding have been identiﬁed as risk
factors.8,13 Ninety-nine percent of the study patients presented
risks factors, with 90.8% reporting the ingestion of non-pasteurized
dairy products, which is considered the most common source of
transmission.3 Higher rates of unpasteurized dairy product
ingestion have been associated with adverse outcomes.8,13,16,17
Occupational status and family history of brucellosis should be
obtained during prenatal care in at-risk areas.
4.1. Clinical presentation
The most common clinical symptoms/signs include fever,
arthralgia, myalgia, hepatosplenomegaly, sweats, fatigue, joint
pain, and anorexia.8,13,18 Similar results were found in the present
study, the most common symptom being fever, followed by
malaise and headache. Fever was high in the acute stages, low
grade and intermittent in the undulant stages, and low grade or
absent in the chronic stages, as described previously.2 The most
common signs were fever and hepato/splenomegaly, similar to
previous reports in non-pregnant women.14 Most of the cases
Table 5
Obstetric outcomes after brucellosis complicating pregnancy (N = 101a)
Obstetric outcome Normal Adverse
Full term delivery
(n = 50), n (%)
Spontaneous
abortion (n = 16), n
(%)
Spontaneous
preterm delivery
(n = 12), n (%)
Fetal death
(n = 7), n (%)
Congenital
malformation (n = 1), n
(%)
Clinical stage
Acute 36 (72.0) 5 (31.3) 8 (66.7) 3 (42.9) 1 100.0)
Subacute 13 (26.0) 9 (56.3) 3 (25.0) 3 (42.9) 0 (0.0)
Chronic 1 (2.0) 2 (12.5) 1 (8.3) 1 (14.3) 0 (0.0)
Trimester
First 17 (34.0) 14 (87.5) 3 (25.0) 4 (57.1) 0 (0.0)
Second 8 (16.0) 2 (12.5) 4 (33.3) 2 (28.6) 1 (100.0)
Third 25 (50.0) 0 (0.0) 5 (41.7) 1 (14.3) 0 (0.0)
Severity of disease
Mild 29 (58.0) 8 (50.0) 7 (58.3) 2 (28.6) 1 (100.0)
Moderate 18 (36.0) 7 (43.8) 4 (33.3) 4 (57.1) 0 (0.0)
Severe 3 (6.0) 1 (6.3) 1 (8.3) 1 (14.3) 0 (0.0)
Treatment status
Before treatment 11 (22.0) 13 (81.3) 4 (33.3) 6 (85.7) 1 (100.0)
After treatment 39 (78.0) 3 (18.8) 8 (66.7) 1 (14.3) 0 (0.0)
a Fifteen of the 101 cases did not have follow-up at the study institution, leaving 86 cases.
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reports in which women were more commonly in the second
trimester.9
Similar to non-pregnant women,2 most of the cases presented
in the acute stage (64.4%). Other authors have reported 76.9% and
100% of acute stage and 7.7% of chronic stage.9,13 It was found that
the subacute and chronic stages most commonly affected the
ﬁrst trimester, and the acute stage affected the third trimester
(p < 0.001). Other studies have failed to ﬁnd this association.13
4.2. Diagnostic criteria
Deﬁnite diagnosis is based on a positive culture,1 with the ideal
tissue being bone marrow.1,19 However, diagnosis traditionally
relies on serology (i.e., agglutination tests, Rose Bengal test). The
rate of positive culture in the present study was 32.7% (B. melitensis
in all cases). Reports in the literature range between 15% and 90%.19
4.3. Medical complications
Osteoarticular disease is the most common complication (i.e.,
sacroiliitis and peripheral arthritis).3,14 We found more sacroiliitis
in the subacute stage, similar to non-pregnant women.14 Sacroiliac
involvement in pregnancy has been described previously.8
Genitourinary disease is the second most common complication.3
In non-pregnant cases, renal complications are rare, but pregnant
women can present renal disease.3,20 Renal involvement was found
in 11.5% in the present study, a frequency higher than those in
previous reports. Liver disease has been described in non-pregnant
series,1,3,14 being the second most common medical complication
in our series, suggesting that pregnant women with brucellosis are
more susceptible to develop liver disease.
The most common medical complication in the present series
was a hematological disease. Hematological disorders have been
described in non-pregnant women,3,21 most frequently anemia.13
Anemia was found in 72.3% of our cases; Crosby et al. found a similar
rate.21 This is of interest due to the well-known role of iron in the
biology of Brucella. Compared to previous reports,21 lower rates of
leukopenia and lymphopenia (the latter considered a prognostic
factor), and a higher rate of leukocytosis (also described in non-
pregnant women) were found in the present series.14 Thrombocy-
topenia was found in 23.1%, which occurs rarely but may cause fatal
central nervous system bleeding.1 Crosby et al. reported higher rates
of thrombocytopenia (39.5%) in non-pregnant women.214.4. Treatment
Over the last few years, only a few systematic reviews and
meta-analyses on the treatment of human brucellosis have been
published.22,23 There have been no clinical trials focusing on
pregnancy. Therefore, cases series and expert opinion publications
guide the management during pregnancy. The selection of the
treatment regimen is based on a few observational studies.24 The
World Health Organization recommends rifampicin as the ﬁrst
line,2 being considered the mainstay of treatment in pregnancy.3 A
second drug (i.e., an aminoglycoside, co-trimoxazole, or erythro-
mycin) should be added to potentiate the bactericidal effect and
decrease recurrence. One meta-analysis supports the use of co-
trimoxazole monotherapy for pregnant women.25 Rifampicin
alone has shown good outcomes,26 and the combination of
ceftriaxone plus rifampicin has been shown to be more effective
than co-trimoxazole plus rifampicin.13 Spontaneous abortion can
occur due to inappropriate treatment,18 and adequate treatment
decreases its risk,9 with 31% of abortion rate reported using co-
trimoxazole plus rifampicin.16 Treatment with co-trimoxazole or
co-trimoxazole plus rifampicin has a strong protective effect
against abortion.9
As described previously,9 it was found that treated patients
most commonly delivered at term. Complications are more
frequent with delayed treatment, with a 10% relapse rate,3 which
are often milder in severity and can be treated with a repeated
course.3
Over the last 40 years, several changes have been made to the
treatment of brucellosis. The First International Meeting on the
Treatment of Human Brucellosis was held in November 2006.27
Selected experts were assigned to review the existing literature. The
recommendation in pregnancy was a co-trimoxazole-containing
regimen, i.e. with rifampicin. Based on our 43-year experience
treating pregnant women with brucellosis, we believe that an
aminoglycoside for 1 week plus rifampicin for 6 weeks is safe and
useful. Our recommendation is to use aminoglycosides for 1 week
plus rifampicin and co-trimoxazole for 6 weeks as the most useful
treatment to date, especially in cases where an early diagnosis has
been made. Aminoglycosides, especially dihydrostreptomycin, have
been associated with ototoxicity after prolonged fetal exposure. In
the era during which pyelonephritis in pregnancy was treated with
short courses of aminoglycosides, hearing impairment in newborns
was not detected. In this series, the long-term follow-up of children
did not reveal any hearing impairment.
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Pregnancy, delivery, and abortion are disease-aggravating
factors.7,15 We found considerable rates of medical complications
with a good response to treatment. Immunological changes during
pregnancy can modify the clinical presentation and prognosis of
some intracellular infectious diseases, such as brucellosis and
typhoid fever.28,29 Adverse outcomes such as spontaneous
abortion,30 preterm delivery, and fetal/maternal death have been
described in the literature, with controversy regarding the
correlation with brucellosis.8,12,13,18,24,26 Complications are fre-
quent in patients with several weeks of disease without treatment,
and early diagnosis and adequate treatment can result in
uncomplicated deliveries. A 55% rate of term deliveries was found
in the present series. Previous series have reported rates between
53.8% and 92%.9,13
Rates of spontaneous abortion due to brucellosis range between
24% and 53%,7–9,12,16 higher than the regular population rate of 8–
20%. The rate in the present series was 18.6%. Other studies have
reported this association.17 Brucellosis should be investigated in
patients from endemic areas with typical symptoms and a history
of spontaneous abortion.16 Prompt diagnosis and treatment
improve outcomes in subsequent pregnancies.16 Spontaneous
abortion usually occurs in the second trimester.9We found higher
rates in the ﬁrst trimester (87.5%). Serum titers have also been
correlated with abortion. The highest rates of abortion have been
reported in B. melitensis-endemic areas, especially among
asymptomatic patients with titers 1:160.7,11,12 Other studies
have failed to show this association.9,16 Recurrent abortion is
associated with chronic stages.31 In the present study, an adverse
obstetric history was found to be signiﬁcantly associated with
chronic stages.
This study showed a 13.9% rate of preterm delivery, higher than
the 11% reported for the overall population. Preterm delivery due
to brucellosis is well recognized,7,17,26 with rates between 7% and
29%.8,12,13 Other intracellular bacteria, such as those causing
typhoid fever, result in an incidence of preterm delivery of
approximately 19%. The rate of fetal death in the present series was
8.1%; fetal death has previously been associated with brucello-
sis,7,17,24 with rates of between 2% and 12%.8,9,12 One case of
congenital malformation was identiﬁed, which could have been
associated not only with brucellosis, but also with the medical
treatment or another unidentiﬁed risk factor. This is difﬁcult to
determine since brucellosis in pregnancy is an infrequent
condition. Also, one case of maternal death occurred; this patient
was misdiagnosed at presentation.
In conclusion, brucellosis in pregnancy is highly associated with
adverse obstetric outcomes including abortion and maternal/fetal
and neonatal death. In endemic areas, cases of unexplained
spontaneous abortion should be investigated for brucellosis.
Prompt diagnosis and treatment decrease the risk of the
devastating adverse obstetric outcomes.
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